ClinicalTrials.gg
RecruitingNCT06915584DRUM-HFUpdated Oct 20, 2026

Drug Management in Heart Failure

An observational study in Heart Failure, sponsored by IRCCS San Raffaele Roma. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by IRCCS San Raffaele Roma · Observational

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 1 year 11 months later.
Updated Oct 20, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
450
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 449 studies in Heart Failure with a site in Italy — 110 open to participants now, 130 under way, 18 of them phase 3. Heart Failure · Italy.

Planned enrollment
67th of 152
450 · median 353
Started
2024
with 33 others
Observational
155 of 449
55 open now
Primary completion
2027-02
later than 63 of 129 live
Registered
403rd of 449
by date

Among the 449 studies in Heart Failure with a site in Italy, this one is the 67th largest by planned enrollment of the 152 observational ones that give a count, is one of 34 that started in 2024, is one of 155 observational ones, reaches primary completion later than 63 of the 129 other live ones, and was the 403rd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

110 of the 449 studies in Heart Failure with a site in Italy are open now. Recruiting first, the newest first:

105 more — sign in →

All 110 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 449 studies in Heart Failure with a site in Italy, or all of them as a file.
02

Study summary

Aim of the proposal is to create an interactive AI-based multicentre prospective database to provide information on how to improve the QoC for pts with HF.This will provide detailed information on pts characteristics,treatment practices, adherence to prescribed guideline-based optimal drug therapy,and outcomes.The database stems from a registry started two years ago,conceived to provide a contemporary snapshot on the adherence to the latest European GGLL for the therapeutic management of pts with HF.The database will be integrated with a specifically designed algorithm that provides an accurate feedback on whether patients are properly treated according to the ESC most recent recommendations.The expected outcomes are:-define non-adherence level to GGLL-based recommendations for treatment of HF;-provide information on initiation, adherence and persistence over time of the recommended treatment;-reduce medical inertia;produce practical implications to reduce morbidity and mortality

Read the detailed description

Heart Failure (HF) is a worldwide leading cause of death and continues to increase, with important implications for healthcare providers. International guidelines (GGLL) for patients with HF recommend a combination of drugs to reduce the risk of events and improve patient¿s symptoms. However, the current impact of guideline-directed medical therapies on mortality and morbidity remains limited because population of HF patients is very different from that enrolled in clinical trials, which is much older and therefore suffers multiple comorbidities, with the need of higher precision therapy based on their phenotype. Therefore, medical inertia is another lack of adherence factor and bad outcomes for HF patients. The aim of the proposal is to create an interactive multicentre prospective database initiated to provide information on how to improve the quality of care for patients (pts) with HF. The database will provide detailed information on pts characteristics, treatment practices, adherence to prescribed guideline, based optimal drug therapy and outcomes. Populations and Methods: The database stems from a registry that started two years ago. This registry was conceived to provide a contemporary snapshot adherence to the latest European guidelines for HF. The database will be integrated with a specifically designed artificial intelligence-based algorithm that provides an accurate feedback on whether patients are properly treated according to the European Society of Cardiology (ESC) most recent and updated recommendations for the treatment of patients with HF, suggesting the right therapy and target dosage based on patients¿ phenotype, clinical characteristic and comorbidities. According to HF drug major trials results, the algorithm will calculate the saved hospitalizations, urgent visits for decompensated HF and death for HF. Using an algorithm, created by inquiring about a recently started HF registry, this project will be able to produce practical implications to reduce morbidity and mortality in pts with HF, thanks to the increase of pts adherence to optimal treatments and physician¿s compliance to GGLL.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Heart Failure
  • Descriptive appropriateness
  • Registry
  • Digital therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

Patients with heart Failure

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Both gender
  • Age >18 years
  • Signed for the study
  • Known diagnosis of heart failure > 6 months
  • Recent or ongoing hospitalization for heart failure exacerbation

Exclusion criteria

Exclusion Criteria:

  • Conditions that, in the investigator's judgment, may interfere with the study or contraindicate participation for safety reasons
  • Concurrent diagnosis of neoplasia
  • Advanced ( \<50%)
  • Advanced valvular heart disease (severe mitral-aortic stenosis-insufficiency requiring cardiac surgery)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
450 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. create a registry that provides an updated assessment of the pattern of use of treatments recommended by guidelines in order to collect new evidence on compliance with them. Be they European or Italian for the treatment of patients with increased cardiov

    Time frame: from enrollment to the end of observation al 24 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Feb 2027, 26 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 26 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Jun 2025 → Feb 2027 and completion Aug 2025 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2025
First posted
Apr 8, 2025
StartActual
Nov 30, 2024
Primary completionEst.
Feb 28, 2027was Jun 2025
CompletionEst.
Mar 31, 2027was Aug 2025
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2025→Feb 28, 2027
Oct 20, 2026
Study completion
Aug 31, 2025→Mar 31, 2027
Oct 20, 2026
Eligibility
Revised
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Primary completion Jun 30, 2025→Feb 28, 2027
    Study completion Aug 31, 2025→Mar 31, 2027
    Eligibility Revised
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06915584
Lead sponsor
IRCCS San Raffaele Roma
Collaborators
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Azienda Ospedaliera Universitaria Mater Domini, Catanzaro
Responsible party
Sponsor
First posted
Apr 8, 2025
Start date
Nov 30, 2024
Primary completion
Feb 28, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Lucia Gatta, PhD
Contact
lucia.gatta@sanraffaele.it
+390652253440

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion